Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction

被引:8
|
作者
Axilrod, Andrew C. [1 ]
机构
[1] Hosp Univ Penn, Div Urol, Philadelphia, PA 19104 USA
关键词
Comorbidities; erectile dysfunction; erection; first-dose success; PDE5; inhibitors; vardenafil;
D O I
10.1185/030079907X242656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Erectile dysfunction (ED) is increasingly being recognized as a sentinel marker of future subsequent cardiovascular disease (CVD). Predicted increases in the prevalence of ED are due to a combination of an aging population and the increasing presence of comorbid conditions (hypertension, dyslipidemia, and diabetes). The dichotomy of the situation is that ED is often associated with these comorbidities, potentially leading to greater CVD risk, and conversely, these comorbidities have also been shown to increase the risk of developing ED. The successful treatment of ED with phosphodiesterase type 5 (PDE5) inhibitor therapy, therefore, is of paramount importance because it not only plays a critical role in restoring erectile function, but also provides clinicians with the opportunity to mitigate existing cardiovascular comorbidities or prevent the occurrence of CVD in this patient population. Methods:This review is based on an electronic literature search of databases, including MEDLINE/PubMed, with information selected for its relevance to PDE5 inhibitor therapy comprising efficacy (e.g., first-dose success) in men with ED with or without comorbidities, onset and duration of action at specific time points, and patient preference. Results: The introduction of PDE5 inhibitors represented a major advance in the treatment of ED. In spite of the availability of these agents, a large percentage of men are still not being treated, in many cases because of their reluctance to seek medical help. Moreover, many men who start treatment with PDE5 inhibitors discontinue treatment. Reasons for discontinuation are many and complex, including lack of initial or first-time success. Although of major concern to both patients and clinicians, there remains limited published clinical data on this specific parameter in the pertinent patient population and from prospective, randomized clinical studies. Conclusion: Data from studies suggests that the available PDE5 inhibitor therapies are effective in treating men with ED, including those who have increased CVD risk and those who have clinically identified cardiovascular comorbidities such as hypertension, dyslipidemia, and/or diabetes. According to data from studies, the attributes of PDE5 inhibitor therapy that matter more to clinicians and patients and that hold influence over treatment compliance include effectiveness in patients with cardiovascular comorbidities, first dose effectiveness or early success, rapid onset of action, reliability, and tolerability.
引用
收藏
页码:3189 / 3198
页数:10
相关论文
共 50 条
  • [41] Safety and efficacy of avanafil, a new phosphodiesterase type-5 (PDE-5) inhibitor for treating erectile dysfunction
    Kaufman, JM
    Dietrich, JW
    JOURNAL OF UROLOGY, 2006, 175 (04): : 299 - 299
  • [42] Erectile dysfunction and cardiovascular considerations: Managing patients effectively with phosphodiesterase type 5 inhibitors - Introduction
    Hutter, AM
    CLINICAL CARDIOLOGY, 2004, 27 (04) : I1 - I2
  • [43] WHAT IS THE OVERALL SAFETY AND EFFICACY OF INHIBITORS OF THE PHOSPHODIESTERASE TYPE 5 ENZYME (PDE5) IN THE TREATMENT OF ERECTILE DYSFUNCTION?
    Ezquer, A. J.
    Gilli, F. A.
    Cenice, F. F.
    JOURNAL OF SEXUAL MEDICINE, 2012, 9 : 89 - 89
  • [44] Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction
    Louizos, Connie C. J.
    Knight, Peter K.
    PHARMACY, 2015, 3 (04): : 295 - 306
  • [45] High frequency of potential phosphodiesterase type 5 inhibitor drug interactions in males with HIV infection and erectile dysfunction
    Cota, Jason M.
    Benavides, Taylor M.
    Fields, John D.
    Jansen, Nathan
    Ganesan, Anuradha
    Colombo, Rhonda E.
    Blaylock, Jason M.
    Maves, Ryan C.
    Agan, Brian K.
    Okulicz, Jason F.
    PLOS ONE, 2021, 16 (05):
  • [46] Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update
    Mulhall, John P.
    Chopra, Ishveen
    Patel, Dipen
    Hassan, Tarek A.
    Tang, Wing Yu
    JOURNAL OF SEXUAL MEDICINE, 2020, 17 (05): : 941 - 948
  • [47] Acute effect of phosphodiesterase type 5 inhibitor on serum oxidative status and prolidase activities in men with erectile dysfunction
    Savas, Murat
    Yeni, Ercan
    Verit, Ayhan
    Gulum, Mehmet
    Aksoy, Nurten
    Ciftci, Halil
    Celik, Hakim
    Altunkol, Adem
    Oncel, Halil
    CLINICS, 2010, 65 (12) : 1311 - 1314
  • [48] Analyzing the Clinical Efficacy of a Type 5 Phosphodiesterase Inhibitor Combined With Ziyin Baihuo Granules in the Treatment of Erectile Dysfunction
    Wang, Rui
    Sun, Wen-Gong
    Zhang, Tian-Biao
    Zheng, Tao
    Lv, Kun-Long
    Nan, Yong-Hao
    Zhang, Wei-Xing
    AMERICAN JOURNAL OF MENS HEALTH, 2022, 16 (06)
  • [49] ERECTILE DYSFUNCTION MANAGEMENT AFTER FAILED PHOSPHODIESTERASE5-INHIBITOR TRIAL: A COST-EFFECTIVENESS ANALYSIS
    Moses, Rachel A.
    Craig, James R.
    Keihani, Sorena
    Myers, Jeremy B.
    Lenherr, Sara M.
    Brant, William O.
    Hotaling, James M.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E558 - E558
  • [50] Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis
    Moses, Rachel A.
    Anderson, Ross E.
    Kim, Jaewhan
    Keihani, Sorena
    Craig, James R.
    Myers, Jeremy B.
    Lenherr, Sara M.
    Brant, William O.
    Hotaling, James M.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 (04) : 387 - 394